Display options
Cite
Lichtenberger LM, Phan T, Fang D, et al. Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs . Oncol Lett. 2018;15(5):6688-6694doi: 10.3892/ol.2018.8098.
Lichtenberger, L. M., Phan, T., Fang, D., & Dial, E. J. (2018). Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs . Oncology letters, 15(5), 6688-6694. https://doi.org/10.3892/ol.2018.8098
Lichtenberger, Lenard M, et al. "Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs ." Oncology letters vol. 15,5 (2018): 6688-6694. doi: https://doi.org/10.3892/ol.2018.8098
Lichtenberger LM, Phan T, Fang D, Dial EJ. Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs . Oncol Lett. 2018 May;15(5):6688-6694. doi: 10.3892/ol.2018.8098. Epub 2018 Feb 21. PMID: 29616131; PMCID: PMC5876429.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2018 May;15(5):6688-6694. doi: 10.3892/ol.2018.8098. Epub 2018 Feb 21.

Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs .

Oncology letters

Lenard M Lichtenberger, Tri Phan, Dexing Fang, Elizabeth J Dial

Affiliations

  1. Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA.

PMID: 29616131 PMCID: PMC5876429 DOI: 10.3892/ol.2018.8098

Abstract

The chemopreventive activity of non-steroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, has been well demonstrated in preclinical and clinical studies. However, the primary side effect from this class of drug is gastrointestinal (GI) bleeding, which has limited the widespread use of NSAIDs for the prevention of cancer. The development of GI-safer NSAIDs, which are associated with phosphatidylcholine (PC) may provide a solution to this therapeutic problem. In the present study, the efficacy of two NSAIDs, aspirin and indomethacin, were compared using murine colon cancer cell line MC-26. Each NSAID was assessed alone and in combination with PC, using

Keywords: aspirin; chemoprevention; colorectal cancer; indomethacin; non-steroidal anti-inflammatory drug

References

  1. Clin Cancer Res. 2014 Mar 1;20(5):1104-13 - PubMed
  2. Semin Oncol. 2016 Feb;43(1):65-77 - PubMed
  3. Br J Pharmacol. 2007 Apr;150(7):913-9 - PubMed
  4. Cancer Res. 1989 Nov 1;49(21):5935-9 - PubMed
  5. Oncol Rep. 2005 Apr;13(4):559-83 - PubMed
  6. Eur J Cancer. 1990;26(7):811-4 - PubMed
  7. Cancer Chemother Pharmacol. 2006 Feb;57(3):295-300 - PubMed
  8. Curr Pharm Des. 2015;21(21):2978-82 - PubMed
  9. Mol Cancer Ther. 2016 Dec;15(12 ):2894-2904 - PubMed
  10. Clin Cancer Res. 2005 Feb 15;11(4):1618-28 - PubMed
  11. Lancet. 2011 Jan 1;377(9759):31-41 - PubMed
  12. Front Immunol. 2016 Sep 22;7:379 - PubMed
  13. Cancer Res. 2003 Feb 1;63(3):586-92 - PubMed
  14. Biosci Biotechnol Biochem. 2014;78(4):672-9 - PubMed
  15. Gastroenterology. 2008 Jan;134(1):21-8 - PubMed
  16. Lancet. 2011 Dec 17;378(9809):2081-7 - PubMed
  17. Cancer Prev Res (Phila). 2017 Feb;10 (2):142-152 - PubMed
  18. Nutr Res. 2015 Aug;35(8):726-35 - PubMed
  19. Digestion. 2012;86(2):171-7 - PubMed
  20. N Engl J Med. 2000 Jun 29;342(26):1946-52 - PubMed
  21. Lancet. 2012 Apr 28;379(9826):1591-601 - PubMed
  22. Gastroenterology. 2004 Jul;127(1):94-104 - PubMed
  23. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 15;309(2):G59-70 - PubMed
  24. Drugs Today (Barc). 2009 Dec;45(12):877-90 - PubMed
  25. Anticancer Res. 2014 Nov;34(11):6277-82 - PubMed
  26. Methods Mol Biol. 2016;1422:297-307 - PubMed
  27. Lancet. 2010 Nov 20;376(9754):1741-50 - PubMed
  28. Cancer Res. 1994 Nov 1;54(21):5602-6 - PubMed
  29. J Clin Oncol. 2015 Nov 1;33(31):3591-7 - PubMed
  30. Int J Colorectal Dis. 2011 Jan;26(1):13-22 - PubMed
  31. Br J Cancer. 2004 Feb 9;90(3):712-9 - PubMed
  32. Int J Oncol. 2004 Mar;24(3):505-12 - PubMed
  33. Curr Pharmacol Rep. 2015 Jun 1;1(3):154-160 - PubMed

Publication Types